Object. Gamma Knife surgery (GKS) is a common treatment for recurrent or residual pituitary adenomas. This study evaluates a large cohort of patients with a pituitary adenoma to characterize factors related to endocrine remis sion, control of tumor growth, and development of pituitary deficiency.
P
ituitary adenomas, which are broadly classified into two groups-functioning (that is, secretory) and nonfunctioning-are fairly common lesions and represent between 10 and 20% of all primary intra cranial tumors. 14, 15 Epidemiological studies have demon strated that up to 20% of the general population has a pituitary adenoma. 14 For both functioning and nonfunctioning pituitary adenomas, incomplete tumor resection or recurrence because of tumor invasion into surrounding structures (for example, the dura mater or cavernous sinus) is com mon. 21, 33 Postsurgical residual secretory adenoma results in the persistence of a hypersecretory state and the as sociated deleterious clinical features. Longterm tumor control rates after microsurgery alone range from 50 to 80%. 4, 6, 14, 15, 18, 19 In patients with a recurrent or residual pi tuitary adenoma, treatment options include repeat resec tion, radiation therapy, medical management, and radio surgery. In 1951, stereotactic radiosurgery was described by Lars Leksell as the "closed skull destruction of an intracranial target using ionizing radiation." 17 In 1968, Leksell treated the first pituitary adenoma patient with the Gamma Knife. Since that time, GKS has been used to treat thousands of patients with a recurrent or residual pituitary adenoma. Many singlecenter, retrospective studies have documented its efficacy. Unfortunately, most reports consist of fewer than 100 patients, making statis tical analysis of such small cohorts problematic. This is an analysis of 418 patients with a recurrent or residual pituitary adenoma who underwent GKS with both com plete neuroimaging and endocrine followup.
Methods

Patient Population
An internal review board-approved, prospectively collected database of patients treated with the Gamma Gamma Knife surgery for pituitary adenomas: factors related to radiological and endocrine outcomes
Clinical article
Knife at the University of Virginia between 1989 and 2006 was reviewed. In that database, 540 patients with a pituitary adenoma were identified. Patients with a minimum of 6 months of endocrine and neuroimaging followup were included (median 31 months; range 6-124 months), resulting in a total of 418 patients in this study. All patients were treated with GKS for a persistent func tioning adenoma or radiological evidence of growth of a nonfunctioning adenoma. Patient characteristics are de tailed in Table 1 .
Preradiosurgical Evaluation
Prior to radiosurgery, patients were evaluated by an endocrinologist and a neurosurgeon. Preradiosurgical evaluation included testing of pituitary and target hor mone levels, including ACTH, cortisol, FSH, LH, IGFI, GH, estrogen, testosterone (men), PRL, TSH, and free T4. In patients with acromegaly, a postoperative oral glucose test was performed. In patients with CD, a 24-hour UFC test was obtained.
Stereotactic Radiosurgery Technique
Radiosurgery was performed using the Gamma Knife; model U was used from 1989 to 2001, model C from 2001 to 2007, and the Perfexion from 2007 to the present. Gamma Knife surgery for patients with pituitary adenoma typically involved multiple isocenters of differ ent beam diameter to achieve a dose plan that conformed to the irregular 3D volumes. In instances in which no dis crete adenoma was detected on MR imaging, but in which there was evidence of persistent hormone hypersecretion, the entire sellar contents and the cavernous sinuses were included in the treatment plan.
At our center, stereotactic frame placement was per formed under monitored anesthesia care in the operat ing room. Stereotactic MR imaging was then performed using thincut axial and coronal sequences through the pituitary region, with both pre and postcontrast sequenc es. Fatsaturation MR protocols were used to minimize postoperative changes that might obscure the accuracy of radiosurgical targeting. Rarely, when MR imaging was contraindicated, stereotactic CT imaging through the sella turcica was performed.
Multiple isocenters along with blocking patterns were used to deliver radiation to the target volume. Tumor margin dose (prescription dose), the radiation dose given to the edge of the pituitary adenoma, was selected by the treating neurosurgeon in conjunction with the radiation oncologist and medical physicist. In patients with a func tioning adenoma, tumor margin doses of 18-30 Gy were typically used. For a nonfunctioning adenoma, margin doses of 12-18 Gy were most commonly administered. Radiosurgical parameters for the patient population are detailed in Table 2 .
The margin dose and treatment isodose were selected based on adenoma volume and type, location, proximity to adjacent radiationsensitive structures, prior radio therapy and radiosurgery (if any), and preexisting cranial neuropathy. Radiation was typically limited to a dose of no more than 8 Gy to 1% of the optic apparatus volume in patients who had no prior radiation or preexisting op tic neuropathy. Typically, this necessitated a clearance of 3-5 mm between the rostral extent of the adenoma and the optic apparatus. Beginning in 2000, patients with ac romegaly or a prolactinoma were instructed to discontin ue a pituitary suppressive medication (dopamine agonist or somatostatin analog) before radiosurgery. The time period for cessation of antisecretory medications varied depending on the pharmacokinetics of the drug; typically 4 weeks for a dopamine agonist and 6-8 weeks for a so matostatin analog.
Postradiosurgical Follow-Up
A thinslice, pituitary adenoma protocol MR imag ing study was obtained at 6-month intervals for the first 2 years after GKS. An MR imaging study was then ob tained at 1year intervals until 5 years after radiosurgery. Patients then underwent followup scans at 2year inter vals. Deviations from the neuroimaging followup proto col were permitted at the discretion of the treating neu rosurgeon or the patient's local physician. Tumor control was defined as either no demonstrable growth or shrink age of the adenoma on followup imaging. Comparisons were made between the latest followup neuroimaging study and the original study obtained for Gamma Knife planning. All neuroimaging studies were evaluated by staff neuroradiologists at the University of Virginia. Endocrine testing was performed contemporane ously with the radiological followup. Testing typically included hormone studies comparable to those of the preradiosurgical evaluation as indicated by the type of adenoma. In all patients with a secretory adenoma, en docrine remission was assessed with the patient having discontinued antisecretory medication. For patients with acromegaly, remission was defined as a normal age-and sexmatched serum IGFI level. Many patients with acro megaly also underwent a postradiosurgical oral glucose test with sequential GH measurements. For patients with prolactinoma, remission was defined as a normal serum PRL level; for those with CD, remission was defined as a normal 24-hour UFC level or ongoing need for corti sol replacement. For detection of new pituitary hormone deficiency, the type and timing of such testing was done at the discretion of the treating endocrinologist. Such test ing typically included measurements of cortisol, thyroid hormone, and gonadal steroid levels. Assessment of GH deficiency was variable.
Statistical Methods
A cumulative database of the 418 patients with pitu itary adenoma was created and analyzed. With the statis tical assistance of the faculty in the Division of Biostatis tics at the University of Virginia, univariate analyses were performed to assess statistically significant factors related to outcomes (p < 0.05). Those factors with a trend toward statistical significance (p < 0.1) are also reported. Odds ratios were determined for statistically significant factors. Where needed, subgroups of the 418patient population were analyzed to make the analysis clinically relevant. A Weibull log-linear model was used to assess significantly different cohorts regarding time to endocrine remission. Univariate and multivariate semiparametric survival analyses were also performed in assessing the time to en docrine remission.
Results
Control of Tumor Growth
All Patients With Pituitary Adenoma. Reliable follow up imaging studies were available in 380 patients with a demonstrable pituitary adenoma on neuroimaging stud ies obtained for GKS planning. Patients without clearly visible tumor (primarily those with CD) were excluded from this analysis because there was no tumor visible at the baseline. In such instances (for patients with CD but no visible tumor; 38 patients), the entire sellar contents were treated with radiosurgery. Because no demonstrable adenoma was seen on the Gamma Knife planning neu roimaging study, followup assessment of tumor control could not be fairly evaluated in these 38 patients.
At the most recent followup evaluation, the tumor volume was unchanged or smaller in 343 patients (90.3%), and there was an increase in tumor volume in 37 patients (9.7%). Typically, adenoma growth was noted at the margin of the planned treatment volume. Tumor margin radiation dose, adenoma volume, length of followup, presence of tumor in the cavernous sinus, suprasellar extension, treat ment of the entire sella, and type of pituitary adenoma were analyzed to determine the relationship with control of tumor growth. Only tumor margin radiation dose cor related significantly with control of tumor growth (p = 0.02). The OR for each 1-Gy increase in the margin dose was 1.062 (95% CI 1.008-1.118). No other factors were found to correlate with control of tumor growth.
Patients With a Secretory Adenoma (Acromegaly and Pro lactinoma).
To determine the effect of suppressive medication on tumor growth following GKS, a subset analysis of patients with acromegaly or a prolactinoma was conducted. Complete neuroimaging followup was available in 135 patients with either acromegaly (108) or a prolactinoma (27) . No tumor growth was observed in 93% of patients (126), and growth occurred in 7% (9) . Control of tumor growth was significantly associated with the tumor margin dose (p = 0.019). For each 1Gy increase in the margin dose, the odds of adenoma volume control were increased by a factor of 1.15 (95% CI 1.022-1.294). Cessation of antisecretory medication at the time of radiosurgery did not correlate with control of tumor volume in this cohort.
Endocrine Remission
All Patients With Secretory Tumors. The endocrine outcomes are shown in Table 3 , and probability values for statistically tested factors are detailed in Table 4 . The results for individual types of secretory adenomas have been reported previously. 10, 11, 20, 32 As shown in Table 3 , the number of patients who achieved remission, the median time to remission, and development of new pituitary hor mone deficiency differed among the tumor types; patients with CD achieved remission the earliest, and patients with Nelson's syndrome typically took the longest time to achieve remission.
The tumor margin radiation dose was inversely re lated to the time to remission (p = 0.019); a higher tu mor margin radiation dose correlated with earlier time to remission (Fig. 1) . Univariate analysis using the Weibull parametric model revealed that a 5Gy reduction in the margin radiation dose predicted an increase in the time to remission by a factor of 1.36 (95% CI 1.05-1.79). There was a trend to significance with smaller tumor size (p = 0.072; Fig. 2 ). With each 1cm 3 reduction in treatment vol ume, the rate of endocrine remission increased by a factor of 1.30 (95% CI 1.05-1.61).
Patients With Acromegaly or a Prolactinoma. This subset analysis was conducted specifically to determine the effect of pituitary suppressive medication on endo crine remission after GKS. Complete endocrine data were available in 162 patients with persistent acromegaly (130) or a prolactinoma (32) . Factors analyzed included the fol lowing: tumor margin radiation dose, tumor size at the time of GKS, tumor in the cavernous sinus, suprasellar extension, treatment of the entire sella and cavernous si nuses, and use of a somatostatin analog (acromegaly) or a dopamine agonist (prolactinoma) at the time of treatment. The median time to remission in those with acromegaly was 29.8 months, and in those with a prolactinoma it was 24.5 months (Table 3 ). There was a trend to remission in patients who were not receiving a suppressive drug (somatostatin analog or dopamine agonist) at the time of treatment (p = 0.067; Fig. 3 ). In patients who were not receiving a suppressive drug, the probability of remission was 1.71 times greater (95% CI 0.96-2.05) than for pa tients receiving medical treatment at the time of GKS. Other Complications. Complications observed in 418 patients included the following: 3 partial III cranial nerve deficits; 1 partial IV cranial nerve deficit, and 1 partial VI cranial nerve deficit. Two of these cranial nerve deficits were permanent. After GKS, new visual acuity or field defi cits were noted in 8 patients. Seventy-five percent of these patients had received prior fractionated radiation therapy. These ophthalmological complications showed no correla tion with radiation dose, tumor volume, adenoma type, or adenoma location. No cases of radiosurgically induced neo plasia or carotid artery injury were observed.
Posttreatment Complications
Discussion
Gamma Knife surgery is a commonly used adjunc tive treatment for patients with a residual or recurrent adenoma, or in patients with persistent hormone hyper secretion. Its efficacy and safety profile have largely been derived from singlecenter, small series of patients con sisting of fewer than 100 individuals, making statistical analysis problematic. [24] [25] [26] 35, 36 Thus, there have been dif fering conclusions about factors that influence outcomes. For example, some studies have shown a benefit to ces sation of pituitary suppressive medications around the time of radiosurgery, whereas others have shown no such benefit. 3, [11] [12] [13] 31, 32 This may be due in part to the limited statistical power of smallcohort analyses.
This study involves the largest group of patients with pituitary adenoma treated with stereotactic radiosurgery yet reported. The novelty of this study is in the assess ment of factors related to endocrine remission and control of tumor growth that could be demonstrated as a result of analyzing 418 patients rather than smaller subgroups. Because our patients were at a single center, the treatment algorithm, radiosurgery, and followup protocol were as consistent as possible. Patients with a nonfunctioning adenoma were treated for persistent or recurrent dis ease, and patients with a functioning pituitary adenoma were treated for ongoing pituitary hormone hypersecre tion. All evaluable patients were assessed for control of tumor growth, new-onset pituitary hormone deficiency, and control of hormone hypersecretion (endocrine remis sion). There are inherent differences (for example, loca tion and volume of adenoma, prescription dose, clinical sequelae, effectiveness of medical management, and so on) between patients with functioning and nonfunction ing adenoma. The goals of radiosurgery for patients with functioning adenoma are adenoma volume control and endocrine remission, whereas for those with nonfunc tioning adenomas the goal is adenoma volume control. Grouping patients with pituitary adenoma together in this study afforded more statistical power to perform a comprehensive analysis that would have been precluded in specific smaller cohorts (for example, our institutional series of patients with CD).
Control of tumor growth occurred in 90% of patients (all types of pituitary adenomas); the higher margin ra diation dose was the only factor that influenced control of tumor growth. Safe total and margin radiation doses were limited by both the size of residual tumor (proximity to the optic nerves, optic chiasm, and cranial nerves) and by previous radiation therapy. 8, 16, 38 Despite these restrictions, acceptable control of tumor growth was achieved.
Endocrine remission varied among patients with the different types of secretory adenomas. Endocrine remis sion in patients with acromegaly or a prolactinoma was correlated with a higher margin radiation dose. In this group of patients, endocrine remission was also associ ated with a trend to statistical significance regarding smaller tumor volume and the absence of pituitary sup pressive medication at the time of Gamma Knife treat ment. Endocrine suppressive medications may alter the tumor's cell cycle and metabolism, making the cells less susceptible to the damaging effects of ionizing radiation. Because of our results and those of other studies (albeit all singlecenter, retrospective studies), in 2000 we instituted a policy of temporarily discontinuing pituitary suppres sive medications (for example, longacting somatostatin analogs and dopamine agonists) before and after GKS so as to maximize the potential for achieving endocrine re mission.
3,11-13,31,32 Our current time for withholding a longacting somatostatin analog, 8 weeks before and 8 weeks after GKS, is based on a study that demonstrated that the longacting somatostatin analog Sandostatin LAR exerts a suppressive effect on GH secretion for up to 8 weeks after administration. 1 Our time for withholding a dop amine agonist drug, 4 weeks before and 4 weeks after Gamma Knife treatment, is arbitrary and could probably be shortened for patients receiving bromocriptine, which is shorter acting than cabergoline. The optimal timing for withholding suppressive medication is not yet known, and is the subject of an ongoing prospective study. Tempo rary cessation of pituitary suppressive medication before and after Gamma Knife treatment is probably low risk, particularly in patients with acromegaly, because the du ration of symptoms and signs is approximately 2.5-10 years before diagnosis, and because patients with a pro lactinoma were not adequately responsive to dopamine agonist therapy, which was the indication for Gamma Knife treatment. 27, 28 New onset of pituitary hormone deficiency occurred in 24.4% of 418 patients; this incidence is similar to that found in other studies. 7, 30, 31 Given the short followup in some patients (all patients in this study had a minimum of 6 months and a median followup of 31 months), it is pos sible that this rate of pituitary hormone deficiency under estimates the true rate of this latent radiosurgeryinduced effect. Prior craniotomy and larger tumor volume were associated significantly with new-onset pituitary deficien cy. Pollock and colleagues 30 reported that patients with an adenoma volume of greater than 4 cm 3 were more likely to develop new pituitary hormone deficiency. This is not surprising, because a larger treatment volume necessarily exposes the normal gland to radiation, and a prior cran iotomy may have caused partial compromise of pituitary function. Reduction in tumor size by transsphenoidal surgery, usually a second operation that is unlikely to be curative (tumor invasion to a surgically inaccessible area), may help reduce the risk of new-onset pituitary deficiency and overall response, although this remains speculative. However, surgical reduction in tumor volume in patients with a prolactinoma resistant to dopamine agonist thera py has been shown to improve the postoperative response to a dopamine agonist in 36% of patients. 9 Additionally, a smaller tumor volume affords the delivery of a higher margin radiation dose, with less risk of necrosis or ra diation injury to adjacent neural structures. Regular en docrine evaluation is necessary to identify new pituitary hormone deficiency and to institute appropriate hormone replacement. In this study, no patient developed panhy popituitarism and one patient developed DI. New onset of DI is an uncommon consequence of GKS; this may have occurred because either the posterior pituitary gland or the hypothalamus (less likely) was affected. This in cidence of DI after Gamma Knife treatment (0.24%) is much lower than that observed after pituitary surgery (16-23% transient, 1.4-2% permanent). 29, 34, 37 Any form of radiation delivery poses some risk of complications. The incidence of complications after Gamma Knife treatment was low, but not zero. New onset loss of pituitary function in this study (24.4%) is a complication that is to be anticipated, diagnosed, and treated promptly. Our study did not demonstrate a sta tistically significant relationship between prior radiation therapy and new onset of a pituitary deficit. This may be a function of the small number of patients receiving prior radiation therapy in our study (that is, 8.3% of the total population) and the existence of baseline pituitary deficits in many patients, thereby reducing the number of patients at risk for newonset hypopituitarism.
The current series is the largest one of patients with pituitary adenoma treated with stereotactic radiosurgery. There are differences in patient selection as well as length and type of followup between the current series and those previously reported in which conventional radia tion therapy was used. 2, 5, 22, 23 Additionally, over the past decade there have been significant technical refinements in radiosurgery and radiation therapy that may alter the risks associated with each. Although our study is not meant to be a direct comparison with series of patients treated with conventional fractionated radiation therapy, the long-term risk of pituitary deficiency following radia tion therapy has been reported to be quite high, with some series noting a risk of more than 50%. It is known that hy popituitarism can develop years after either radiosurgery or radiation therapy. The rate of hypopituitarism reported in this series and others is probably an underestimate of the true incidence of this complication. Of more concern is the potential for damage to the visual system or cranial nerves. Although much is known about radiation toler ance of the optic nerves, optic chiasm, and cranial nerves, this study suggests that there is still much to learn about what constitutes a safe dose to these neural structures.
This study is not without limitations. Longer follow up and a larger population size will be required to better define the true risk-to-benefit profile of stereotactic radio surgery for patients with recurrent or residual pituitary adenomas. Because it was performed at a center treating pituitary patients referred from throughout the world, patient selection may inherently introduce a bias to this study. Additionally, technological advances in endocrine testing and management, neuroimaging, microsurgery, and radiosurgery throughout the nearly 20year accrual period for patients in this study probably introduced some heterogeneity (and hopefully improvement) to outcomes. As with any KaplanMeier type plot, the later time points depicted in Figs. 1-3 are based on fewer patients than the earlier ones. Extrapolation of too much significance from the later time points should be avoided.
Conclusions
This study demonstrates that GKS provides reason able rates of control of tumor growth and endocrine re mission. A higher margin dose and a smaller treatment volume probably offer a greater probability of achieving these goals. New-onset pituitary hormone deficiency was the most common side effect. Decreasing the adenoma volume by resection and temporarily withholding pitu itary suppressive medications seem to be prudent ap proaches prior to radiosurgery.
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